![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | increases expression | ISO | RGD:1616706 | 6480464 | ethylene dichloride results in increased expression of SLC18B1 mRNA | CTD | PMID:28189721 | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:1616706 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SLC18B1 mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1315874 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC18B1 mRNA | CTD | PMID:20106945, PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC18B1 mRNA | CTD | PMID:33387578 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1616706 | 6480464 | Fenretinide results in decreased expression of SLC18B1 mRNA | CTD | PMID:28973697 | acrylamide | decreases expression | ISO | RGD:1315874 | 6480464 | Acrylamide results in decreased expression of SLC18B1 mRNA | CTD | PMID:32763439 | all-trans-retinoic acid | increases expression | ISO | RGD:1315874 | 6480464 | Tretinoin results in increased expression of SLC18B1 mRNA | CTD | PMID:21934132 | AM-251 | decreases expression | ISO | RGD:1315874 | 6480464 | AM 251 results in decreased expression of SLC18B1 mRNA | CTD | PMID:16500647 | aristolochic acid A | decreases expression | ISO | RGD:1315874 | 6480464 | aristolochic acid I results in decreased expression of SLC18B1 mRNA | CTD | PMID:33212167 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SLC18B1 mRNA | CTD | PMID:25181051 | calcitriol | decreases expression | ISO | RGD:1315874 | 6480464 | Calcitriol results in decreased expression of SLC18B1 mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | RGD:1315874 | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SLC18B1 mRNA | CTD | PMID:21592394 | copper(II) sulfate | decreases expression | ISO | RGD:1315874 | 6480464 | Copper Sulfate results in decreased expression of SLC18B1 mRNA | CTD | PMID:19549813 | cyclosporin A | decreases expression | ISO | RGD:1315874 | 6480464 | Cyclosporine results in decreased expression of SLC18B1 mRNA | CTD | PMID:20106945, PMID:25562108 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of SLC18B1 mRNA | CTD | PMID:21266533 | dioxygen | multiple interactions | ISO | RGD:1616706 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of SLC18B1 mRNA | CTD | PMID:30529165 | dorsomorphin | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1616706 | 6480464 | Doxorubicin results in decreased expression of SLC18B1 mRNA | CTD | PMID:28608983 | entinostat | increases expression | ISO | RGD:1315874 | 6480464 | entinostat results in increased expression of SLC18B1 mRNA | CTD | PMID:26272509, PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA | CTD | PMID:27188386 | finasteride | increases expression | EXP | | 6480464 | Finasteride results in increased expression of SLC18B1 mRNA | CTD | PMID:24136188 | fluoranthene | multiple interactions | ISO | RGD:1616706 | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC18B1 mRNA | CTD | PMID:28329830 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of SLC18B1 mRNA | CTD | PMID:24136188 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of SLC18B1 mRNA | CTD | PMID:24793618 | folic acid | multiple interactions | ISO | RGD:1616706 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SLC18B1 mRNA | CTD | PMID:22206623 | hydrogen peroxide | affects expression | ISO | RGD:1315874 | 6480464 | Hydrogen Peroxide affects the expression of SLC18B1 mRNA | CTD | PMID:20044591 | ivermectin | decreases expression | ISO | RGD:1315874 | 6480464 | Ivermectin results in decreased expression of SLC18B1 protein | CTD | PMID:32959892 | manganese(II) chloride | increases expression | EXP | | 6480464 | manganese chloride results in increased expression of SLC18B1 mRNA | CTD | PMID:28801915 | methyl methanesulfonate | decreases expression | ISO | RGD:1315874 | 6480464 | Methyl Methanesulfonate results in decreased expression of SLC18B1 mRNA | CTD | PMID:23649840 | methylmercury chloride | decreases expression | ISO | RGD:1315874 | 6480464 | methylmercuric chloride results in decreased expression of SLC18B1 mRNA | CTD | PMID:27188386 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of SLC18B1 mRNA | CTD | PMID:24136188 | nickel sulfate | increases expression | ISO | RGD:1315874 | 6480464 | nickel sulfate results in increased expression of SLC18B1 mRNA | CTD | PMID:22714537 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of SLC18B1 mRNA | CTD | PMID:24136188 | panobinostat | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA | CTD | PMID:27188386 | panobinostat | increases expression | ISO | RGD:1315874 | 6480464 | panobinostat results in increased expression of SLC18B1 mRNA | CTD | PMID:26272509 | paracetamol | decreases expression | ISO | RGD:1315874 | 6480464 | Acetaminophen results in decreased expression of SLC18B1 mRNA | CTD | PMID:21420995, PMID:29067470 | paraquat | increases expression | ISO | RGD:1315874 | 6480464 | Paraquat results in increased expression of SLC18B1 mRNA | CTD | PMID:34097952 | pirinixic acid | increases expression | ISO | RGD:1616706 | 6480464 | pirinixic acid results in increased expression of SLC18B1 mRNA | CTD | PMID:23811191 | pregnenolone 16alpha-carbonitrile | decreases expression | ISO | RGD:1616706 | 6480464 | Pregnenolone Carbonitrile results in decreased expression of SLC18B1 mRNA | CTD | PMID:28903501 | quercetin | decreases expression | ISO | RGD:1315874 | 6480464 | Quercetin results in decreased expression of SLC18B1 mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | decreases expression | ISO | RGD:1616706 | 6480464 | sodium arsenite results in decreased expression of SLC18B1 mRNA | CTD | PMID:36209798 | sulindac | increases expression | EXP | | 6480464 | Sulindac results in increased expression of SLC18B1 mRNA | CTD | PMID:24136188 | testosterone | decreases expression | ISO | RGD:1315874 | 6480464 | Testosterone results in decreased expression of SLC18B1 mRNA | CTD | PMID:21592394 | testosterone | multiple interactions | ISO | RGD:1315874 | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SLC18B1 mRNA | CTD | PMID:21592394 | tetrachloromethane | decreases expression | ISO | RGD:1616706 | 6480464 | Carbon Tetrachloride results in decreased expression of SLC18B1 mRNA | CTD | PMID:31919559 | thimerosal | decreases expression | ISO | RGD:1315874 | 6480464 | Thimerosal results in decreased expression of SLC18B1 mRNA | CTD | PMID:27188386 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of SLC18B1 mRNA | CTD | PMID:34492290 | trichostatin A | increases expression | ISO | RGD:1315874 | 6480464 | trichostatin A results in increased expression of SLC18B1 mRNA | CTD | PMID:24935251 more ... | trichostatin A | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA | CTD | PMID:27188386 | urethane | decreases expression | ISO | RGD:1315874 | 6480464 | Urethane results in decreased expression of SLC18B1 mRNA | CTD | PMID:28818685 | valproic acid | decreases expression | ISO | RGD:1315874 | 6480464 | Valproic Acid results in decreased expression of SLC18B1 mRNA | CTD | PMID:29154799 | valproic acid | affects expression | ISO | RGD:1315874 | 6480464 | Valproic Acid affects the expression of SLC18B1 mRNA | CTD | PMID:25979313 | valproic acid | increases expression | ISO | RGD:1315874 | 6480464 | Valproic Acid results in increased expression of SLC18B1 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA | CTD | PMID:27188386 | vinclozolin | decreases methylation | EXP | | 6480464 | vinclozolin results in decreased methylation of SLC18B1 gene | CTD | PMID:30207508 | vorinostat | increases expression | ISO | RGD:1315874 | 6480464 | vorinostat results in increased expression of SLC18B1 mRNA | CTD | PMID:26272509, PMID:27188386 | vorinostat | multiple interactions | ISO | RGD:1315874 | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA | CTD | PMID:27188386 | |